title: Supplementation with a 9c,11t-rich conjugated linoleic acid blend shows no clear inhibitory effects on platelet function in healthy subjects at low and moderate cardiovascular risk: a randomized controlled trial.
abstract: METHODS
  The 9cis,11trans-conjugated linoleic acid (9c,11t-CLA) is reported to have anti-atherogenic properties in animal models and to modulate protein expression in unstimulated human platelets in vivo. Platelet function was therefore investigated after dietary supplementation with 9c,11t-CLA enriched oil (CLA80:20) in a randomized, baseline-controlled cross-over trial.
  
  
  RESULTS
  Forty-three healthy adults at low to moderate risk of cardiovascular disease received 4 g/day of CLA80:20 or placebo for two weeks each. Platelet function, inflammation, and endothelial activation were assessed before and after each phase. Compared with placebo, supplementation had no significant effects on platelet function measured by Platelet Function Analyzer-100. Inhibitory effects on collagen-induced aggregation were sex-dependent (p = 0.005) that reached significance only in women (p = 0.045). Thrombin receptor-activating peptide (TRAP)-induced P-selectin expression was higher after supplementation in all subjects (p = 0.017). TRAP-induced platelet fibrinogen binding was also dependent on sex (p = 0.015), with fibrinogen binding after CLA80:20 being higher in males (p = 0.035). Plasma monocyte chemoattractant protein-1 was higher (p = 0.041) after CLA80:20.
  
  
  CONCLUSIONS
  No clear evidence was found for inhibition or activation of platelet function as well as inflammation by CLA80:20 in a low to moderate cardiovascular risk group.
authors: The Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK.
authors: Eva-Maria
authors: EM
authors: Bachmair
authors: Sharon G
authors: SG
authors: Wood
authors: Hiskias G
authors: HG
authors: Keizer
authors: Graham W
authors: GW
authors: Horgan
authors: Isobel
authors: I
authors: Ford
authors: Baukje
authors: B
authors: de Roos
mesh_terms: D000328:Adult; D050197:Atherosclerosis / Q000188:drug therapy; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control; D018932:Chemokine CCL2 / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D018592:Cross-Over Studies; D019587:Dietary Supplements; D004311:Double-Blind Method; D023381:Endpoint Determination; D005215:Fasting; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D044243:Linoleic Acids, Conjugated / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D044243:Linoleic Acids, Conjugated; D014280:Triglycerides
keywords: Cardiovascular disease risk; Conjugated linoleic acid; Dietary intervention; Platelet function